Dabur Research Foundation, established in 1979 is an Oncology focused Research Organization based in India. We are the research arm of Dabur Pharma having more than 15 years of expertise in Discovery & Development of cytotoxics and Targeted Oncologicals. Our R&D Center is spread over 60,000 sq. ft and we have a team of more than 220 scientists trained to carry out cutting edge research & development activities in Oncology. Our in-house discovery programs have generated a robust pipeline of molecules that are at various stages of development. These include Nanoxel
TM a first to the world polymeric nanoparticle based drug delivery system, which was launched in India early this year. Another molecule, DRF 7295, currently in Phase II clinical development is a peptide based targeted drug for the treatment of gastrointestinal carcinomas.
Our contract services are designed to Accelerate Discovery & Development in Oncology. We provide a range of integrated services & independent modules customized to meet client requirements.
- Pre-clinical Biology Packages from Hit Identification to pre-IND Candidate Selection
- SMART (Screening Module for Accelerating Anticancer Research And Therapeutics)
- SAFETY (Screens Available For Frequently Encountered ToxicitY)
- Independent Preclinical Biology Modules including:
- Cytotoxicity, Xenograft, ADMET, Target based screening, Apoptosis, Angiogenesis, Protein Cloning and Expression, Chemotherapy induced Cardiotoxicity and Alopecia
- Chemistry Services for Process Development, Optimization & Scale-up
- Isolation and Characterization of Active Principles from Medicinal Plants
- Custom Synthesis of Peptides
- Analytical Services including Impurity Profiling and Stability Studies
- Co-Development of Nano-polymer & Liposome based Drug Delivery Systems
- Formulation Development of Solid & Injectable Dosage forms for Cytotoxics
- Phase II to Phase IV Clinical Trials
